LBP and CD14 polymorphisms correlate with increased colorectal carcinoma risk in Han Chinese

Rui Chen, Fu-Kang Luo, Ya-Li Wang, Jin-Liang Tang, You-Sheng Liu

Rui Chen, You-Sheng Liu, Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
Fu-Kang Luo, Department of Laboratory Medicine, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
Ya-Li Wang, Jin-Liang Tang, Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China

Author contributions: Chen R and Liu YS designed research; Chen R and Luo FK performed research; Wang YL and Tang JL provided new reagents/analytic tools; Chen R, Liu YS and Luo FK analyzed data; and Chen R and Liu YS wrote the paper.

Supported by The National Natural Science Foundation of China, No.30571924
Correspondence to: You-Sheng Liu, PhD, Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. ysliu01@yahoo.com.cn
Telephone: +86-23-68765460 Fax: +86-23-68765460
Received: February 21, 2011 Revised: April 11, 2011 Accepted: April 18, 2011 Published online: May 14, 2011

Abstract

AIM: To explore the associations of polymorphisms of lipopolysaccharide binding protein (LBP), cluster of differentiation 14 (CD14), toll-like receptor 4 (TLR-4), interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) with the colorectal carcinoma (CRC) risk in Han Chinese.

METHODS: Polymorphisms of LBP (rs1739654, rs2232596, rs2232618), CD14 (rs77083413, rs4914), TLR-4 (rs5030719), IL-6 (rs13306435) and TNF-α (rs35131721) were genotyped in 479 cases of sporadic colorectal carcinoma and 486 healthy controls of Han Chinese in a case-control study. Single-nucleotide polymorphisms (SNPs) between cases and controls were analyzed by unconditional logistic regression.

RESULTS: GA and GG genotypes of LBP rs2232596 were associated with a significantly increased risk of CRC [odds ratio (OR) = 1.51, 95% confidence interval (CI) 1.15-1.99, P = 0.003; OR = 2.49, 95% CI 1.16-5.38, P = 0.016, respectively]. A similar association was also observed for the CG genotype of CD14 rs4914 (OR = 1.69, 95% CI 1.20-2.36, P = 0.002). In addition, a combination of polymorphisms in LBP rs2232596 and CD14 rs4914 led to a 3.4-fold increased risk of CRC (OR = 3.44, 95% CI 1.94-6.10, P = 0.000).

CONCLUSION: This study highlights the LBP rs2232596 and CD14 rs4914 polymorphisms as biomarkers for elevated CRC susceptibility in the Chinese Han population.

Key words: Colorectal carcinoma; Cluster of differentiation 14; Lipopolysaccharide binding protein; Single-nucleotide polymorphisms

Peer reviewer: Vito Annese, MD, Department of Internal Medicine, Unit of Gastroenterology, Hospital, Viale Cappuccini, 1, San Giovanni Rotondo 71013, Italy

Chen R, Luo FK, Wang YL, Tang JL, Liu YS. LBP and CD14 polymorphisms correlate with increased colorectal carcinoma risk in Han Chinese. World J Gastroenterol 2011; 17(18): 2326-2331 Available from: URL: http://www.wjgnet.com/1007-9327/full/v17/i18/2326.htm DOI: http://dx.doi.org/10.3748/wjg.v17.i18.2326

INTRODUCTION

Colorectal carcinoma (CRC) is one of the major causes of cancer death throughout the world. In China, the incidence rate of newly diagnosed CRC cases is increasing rapidly. Both environmental and genetic factors contribute to the tumorigenesis of CRC. The classical adenoma-carcinoma sequence model proposes that genetic mutations of K-ras, adenomatous polyposis coli (APC), the deleted in colorectal cancer (DCC), and p53 play important roles in the malignant transformation and cancer progression.
of CRC\textsuperscript{[3]}. Recent studies have demonstrated that chronic inflammation is also an important factor in the carcinogenesis of CRC\textsuperscript{[4,5]}. In the tumor microenvironment, inflammatory cells, especially the so-called tumor-associated macrophages (TAMs), induce suppression of host antitumor activities, stimulate tumor cell growth, and promote malignant transformation, angiogenesis and metastasis\textsuperscript{[6-8]}. TAMs are key regulatory components of cancer-related inflammation. TAMs mainly derive from monocyctic precursors in blood circulation, and are recruited to the tumor sites by tumor-derived chemokines such as C-C motif ligand 2 (CCL2) as well as cytokines in the tumor microenvironment, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF) and macrophage colony stimulating factor (M-CSF). These chemokines and cytokines also regulate the survival and differentiation of TAMs\textsuperscript{[9,10]}. Further studies have demonstrated that TAMs are defective in IFN-\gamma/lipopolysaccharide (LPS) responsiveness to bacterial invasion\textsuperscript{[11]}. In solid tumors, TAMs are reprogrammed to have pro-tumor properties and therefore fail to respond to LPS stimulation that should have killed the cancer cells\textsuperscript{[12]}. Whether LPS-induced signaling pathways play important roles in tumor progression warrants further investigation.

Lipopolysaccharide binding protein (LBP), cluster of differentiation 14 (CD14), and toll-like receptor 4 (TLR-4) are pattern-recognition receptors (PRRs) that mediate innate immune response to LPS challenge\textsuperscript{[13,14]}. LBP is a secretory class I acute phase protein, which can drastically increase LPS-induced activation of immune cells by binding with LPS and transferring it to CD14. CD14 is a glycosylphosphatidylinositol (GPI)-linked LPS receptor which exists as either soluble forms in the serum. TLR4 belongs to a family of innate immune receptors expressed on the surface of monocytes and macrophages, recognizing pathogen-associated molecular patterns (PAMPs) such as LPS. In the LPS signaling pathway, TLR4 can specifically recognize LPS with the aid of LBP, CD14 and MD-2 molecular complex and activate macrophages in response to LPS-induced inflammation.

Genetic variations of inflammatory factor genes are correlated with increased risk in several malignant tumors. Previous studies have demonstrated a strong association between IL-1beta, IL-8 polymorphisms and gastric carcinoma\textsuperscript{[15,16]}, IL-6 polymorphism and cervical carcinoma\textsuperscript{[17]}, IL-8, IL-10, TLR4 polymorphisms and prostate carcinoma\textsuperscript{[18,19]}, TNF-\alpha polymorphism and non-small cell lung cancer\textsuperscript{[20]}. However, the association between polymorphisms of LPS-signaling-related genes and CRC susceptibility in the Chinese Han population remains elusive. In this study, we directly addressed this issue and investigated the association between polymorphisms of LBP, CD14, TLR4, IL-6 and TNF-\alpha genes and the CRC risk in a case-control study.

**MATERIALS AND METHODS**

**Study population**

All subjects were genetically unrelated Chinese Han people living in the southwest region of China. The characteristics of CRC cancer patients and controls included in this study are summarized in Table 1. Patients were chosen from Chongqing Xinqiao Hospital, the second affiliated hospital of Third Military Medical University who were treated from 2008 to 2010. The diagnosis of CRC was confirmed histologically. Patients with histories of previous cancers other than CRC and radiotherapy or chemotherapy were excluded. The controls were healthy people matched to cases by age, sex and dietary habits. Informed consent was obtained from all subjects and the study was approved by the Ethical Committee of Third Military Medical University. Individuals who had smoked over 100 cigarettes were classified as smokers, including current smokers and former smokers who had stopped smoking for at least one year. Individuals who had been drinking alcohol at least once a week for more than 6 months were labeled as drinkers, including current drinkers and former drinkers. Former drinkers were those who had abstained from drinking for more than one year.

| Parameters                  | Cases     | Controls   | P value |
|-----------------------------|-----------|------------|---------|
| Age (mean ± SD, yr)         | 57.85 ± 10.05 | 58.10 ± 13.47 | 0.751   |
| Sex                         |           |            |         |
| Male                        | 259 (54.1) | 254 (52.3) |         |
| Female                      | 220 (45.9) | 222 (47.7) |         |
| Total                       | 479       | 486        | 0.574   |
| Smoking status              |           |            |         |
| Never                       | 334 (69.7) | 357 (73.5) |         |
| Former                      | 15 (3.1)   | 39 (8.0)   |         |
| Present                     | 130 (27.1) | 90 (18.5)  |         |
| Total                       | 479       | 486        | 0.199   |
| Drinking status             |           |            |         |
| Never                       | 10 (2.1)   | 16 (3.3)   |         |
| Former                      | 280 (58.5) | 207 (42.6) |         |
| Present                     | 189 (39.5) | 263 (54.1) |         |
| Total                       | 479       | 486        | 0.248   |

**DNA extraction, polymorphism selection and genotyping**

Genomic DNA was extracted from whole blood samples of subjects by the TIANamp Blood DNA Kit (Tiangen, China) according to the manufacturer’s instructions. Eight polymorphisms in 5 genes (rs1739654, rs2232596 and rs2232618 in LBP; rs4914 and rs77083413 in CD14; rs5030719 in TLR4; rs13306435 in IL-6; and rs35131721 in TNF-\alpha) examined in our study have been reported with
the minor allele frequency over 1%\(^{[2]}\). SNP genotyping was carried out by the two-step SNaPshot assay. The first step was amplification of gene fragments containing these polymorphic sites. The polymerase chain reaction (PCR) was performed in 25 μL reaction mixture containing 1 × master mix (Tiangen, China), 30 ng genomic DNA templates and 0.4 μmol/L primer sets. Primer sequences (5' to 3') were presented in the order of forward, reverse and SNaPshot sequences, including LBP rs1739654: ACAGAATGCAAGGGCACACCTCT, CCTGAGGCTCTCTCTCTCCTC, GCCGCCAGGGAGGCTAT; LBP rs2232596: TCACACTGGACCTCATAAGG, GCCTTGGCCCTTAATTACTTCT, CATGTTTTTCAGATTTTGAGA AATGATCCAGAAAT; LBP rs2232618: TATGTTGGCACACACAGACCCA, CACTCTCATGTCCTCCTCTGTC, GCACCCTCAACTATTACATCTTTAACCC; CD14 rs77083413: TGAAATTGCCAAAAGTCTCTCA, CCCTGAACTCTCTCATACTCTGTC, TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
The LPS-signaling pathway is a crucial player in the innate immunity regulatory system, which includes LBP, CD14, TLR4/MD2 and other molecules involved in LPS-induced NF-κB activation such as MyD88, TIR, IRAK and TRAF6[22]. In intestinal mucosa, continuous exposure to LPS activates M1 type macrophages to perform tumoricidal tasks. TAMs in the cancer micro-environment belong to M2 macrophages and, on the contrary, promote tumor growth. In the presence of M2 macrophages, the LPS signaling pathway is down-regulated but the mechanisms remain unclear[10-12].

Previous studies in this field mainly focused on the effects of genetic variations of aforementioned genes in non-tumoral diseases such as bacterial infections[23,24], sepsis[25] and myocardial infarction[26]. Recently, how these genetic variations contribute to the risk of developing var-

Table 2  Genes, polymorphism and frequencies in colorectal carcinoma cases and controls

| SNP       | Genotype | Cases (n = 479) | Controls (n = 486) | Odds ratio (95% CI) | ^p value |
|-----------|----------|----------------|-------------------|---------------------|---------|
| LBP       | GG       | 377 (78.7%)    | 360 (74.1%)       | 0.75 (0.55-1.02)    | 0.07    |
| rs1739654 | GA       | 93 (19.4%)     | 118 (24.3%)       | 1.07 (0.41-2.82)    | 0.88    |
|           | AA       | 9 (1.9%)       | 8 (1.6%)          | 0.77 (0.57-1.04)    | 0.09    |
| rs2232596 | GA+AA    | 102 (21.3%)    | 126 (25.9%)       | 1.51 (1.15-1.99)    | 0.003   |
|           | AA       | 28 (60.3%)     | 343 (70.6%)       | 2.49 (1.16-5.38)    | 0.016   |
| rs2232618 | GA+GG    | 190 (39.7%)    | 143 (29.4%)       | 1.58 (1.21-2.06)    | 0.001   |
|           | TT       | 385 (80.4%)    | 396 (81.5%)       | 1.09 (0.79-1.50)    | 0.613   |
|           | CT       | 93 (19.4%)     | 88 (18.1%)        | 0.51 (0.05-5.70)    | 0.581   |
|           | CC       | 9 (1.9%)       | 90 (18.5%)        | 1.07 (0.78-1.48)    | 0.662   |
| CD14      | GG       | 403 (84.1%)    | 400 (82.3%)       | 0.858 (0.605-1.215) | 0.388   |
| rs77083413| GC       | 70 (14.6%)     | 81 (16.7%)        | 1.19 (0.36-3.93)    | 0.744   |
|           | CC       | 6 (1.3%)       | 5 (1%)            | 0.88 (0.63-1.23)    | 0.447   |
| rs4914    | CC+CC    | 76 (15.9%)     | 86 (17.7%)        | 1.69 (1.20-2.36)    | 0.002   |
|           | CG       | 102 (21.3%)    | 68 (14%)          | 3.00 (0.79-11.39)   | 0.091   |
|           | GG       | 8 (1.7%)       | 3 (0.6%)          | 1.74 (1.12-2.42)    | 0.001   |
| IL-6      | TT       | 415 (86.6%)    | 420 (84.6%)       | 0.93 (0.64-1.36)    | 0.725   |
| rs13306435| AT       | 60 (12.5%)     | 65 (13.4%)        | 4.05 (1.45-36.37)   | 0.177   |
|           | AA       | 4 (0.9%)       | 2 (0.4%)          | 1.27 (0.45-4.03)    | 0.001   |
|           | AT+AA    | 64 (13.4%)     | 66 (13.6%)        | 0.98 (0.68-1.42)    | 0.921   |

1Adjusted for age, sex, smoking and drinking status.

Table 3  Stratification analyses for rs2232596 by smoking or drinking status

| Genotype frequencies (%) | Status | Cases (n = 479) | Controls (n = 486) | ^p value | Odds ratio (95% CI) |
|--------------------------|--------|----------------|-------------------|---------|--------------------|
| Smoking                  |        |                |                   |         |                    |
| AA                       | No     | 131 (27.3%)    | 155 (31.9%)       |         |                    |
| GA                       | No     | 59 (12.3%)     | 55 (11.3%)        | 0.303   | 1.26 (0.81-1.95)   |
| GG                       | No     | 10 (2.1%)      | 5 (1.0%)          | 0.292   | 1.86 (0.59-5.87)   |
| GA/GG                    | No     | 69 (14.4%)     | 60 (12.3%)        | 0.190   | 1.32 (0.87-2.02)   |
| AA                       | Yes    | 158 (33.0%)    | 188 (38.7%)       |         |                    |
| GA                       | Yes    | 100 (20.9%)    | 78 (16.0%)        | 0.005   | 1.68 (1.17-2.40)   |
| GG                       | Yes    | 11 (2.3%)      | 5 (1.0%)          | 0.084   | 2.59 (0.88-7.63)   |
| GA/GG                    | Yes    | 111 (23.2%)    | 85 (17.0%)        | 0.002   | 1.73 (1.22-2.46)   |
| Drinking                 |        |                |                   |         |                    |
| AA                       | No     | 6 (1.3%)       | 9 (1.9%)          |         |                    |
| GA                       | No     | 4 (0.8%)       | 6 (1.2%)          | 0.892   | 0.89 (0.16-5.07)   |
| GG                       | No     | 0 (0%)         | 1 (0.2%)          | 0.998   |                    |
| GA/GG                    | No     | 4 (0.8%)       | 7 (1.4%)          | 0.739   | 0.75 (0.14-4.03)   |
| AA                       | Yes    | 283 (59.1%)    | 334 (69.7%)       |         |                    |
| GA                       | Yes    | 165 (34.4%)    | 127 (26.1%)       | 0.003   | 1.53 (1.16-2.03)   |
| GG                       | Yes    | 21 (4.4%)      | 9 (1.9%)          | 0.015   | 2.68 (1.21-5.97)   |
| GA/GG                    | Yes    | 186 (38.8%)    | 136 (28.0%)       |         | 1.61 (1.23-2.11)   |

1Adjusted for age, sex, and drinking or smoking status.
Table 4 Stratification analyses for rs4914 by smoking or drinking status

| Genotype frequencies (%) | Status | Cases (n = 479) | Controls (n = 486) | \(^P\) value | Odds ratio (95% CI) |
|-------------------------|--------|----------------|-------------------|-------------|---------------------|
|                         | Smoking |                |                   |             |                     |
| CC                      | No      | 146 (30.5%)    | 191 (39.3%)       | 0.000       | 2.820 (1.64-4.85)   |
| CG                      | No      | 50 (10.4%)     | 23 (4.7%)         | 0.144       | 5.210 (0.57-47.55)  |
| GG                      | No      | 4 (0.8%)       | 1 (0.2%)          |             |                     |
| CG/GG                   | No      | 54 (11.2%)     | 24 (4.9%)         | 0.000       | 2.920 (1.72-4.96)   |
| CC                      | Yes     | 223 (46.6%)    | 224 (46.1%)       |             |                     |
| CG                      | Yes     | 52 (10.9%)     | 45 (9.3%)         | 0.524       | 1.155 (0.74-1.80)   |
| GG                      | Yes     | 4 (0.8%)       | 2 (0.4%)          | 0.430       | 1.993 (0.36-11.05)  |
| CG/GG                   | Yes     | 56 (11.7%)     | 47 (9.7%)         | 0.429       | 1.190 (0.77-1.83)   |
|                         | Drinking |            |                   |             |                     |
| CC                      | No      | 9 (1.9%)       | 10 (2.1%)         | 0.215       | 0.227 (0.02-3.27)   |
| CG                      | No      | 1 (0.2%)       | 5 (1.0%)          |             |                     |
| GG                      | No      | 0 (0%)         | 1 (0.2%)          | 0.998       |                     |
| CG/GG                   | No      | 1 (0.2%)       | 6 (1.2%)          | 0.154       | 0.190 (0.02-1.88)   |
| CC                      | Yes     | 360 (75.2%)    | 405 (83.3%)       |             |                     |
| CG                      | Yes     | 101 (21.1%)    | 63 (13.0%)        | 0.001       | 1.800 (1.28-2.53)   |
| GG                      | Yes     | 8 (1.7%)       | 2 (0.4%)          | 0.060       | 4.470 (0.94-21.18)  |
| CG/GG                   | Yes     | 109 (22.8%)    | 65 (13.4%)        | 0.000       | 1.890 (1.34-2.64)   |

\(^1\) Adjusted for age, sex and drinking or smoking status.

Table 5 Colorectal carcinoma risk with combined lipopolysaccharide binding protein rs2232596 and CD14 rs4914 SNPs

| No. of risk genotype | Cases (n = 479) | Controls (n = 486) | \(^P\) value | Odds ratio (95% CI) |
|----------------------|----------------|-------------------|-------------|---------------------|
| “0”                  | 235 (49.1%)    | 296 (60.9%)       | 0.000       | 1.46 (1.11-1.92)    |
| “1”                  | 194 (40.5%)    | 172 (35.4%)       | 0.007       | 3.44 (1.94-6.10)    |
| “2”                  | 50 (10.4%)     | 18 (3.7%)         | 0.000       | 16.66 (1.28-215)    |
| “1+2”                | 244 (50.9%)    | 190 (39.1%)       | 0.000       | 1.66 (1.28-2.15)    |

\(^1\) Adjusted for age, sex, smoking and drinking status.

Various cancers have drawn much attention. Polymorphisms in the CD14 promoter can affect the susceptibility to CRC and Helicobacter pylori infection–related gastric carcinoma in Chinese patients, and prostate cancer in African American men. Effects of polymorphisms of TLR4 and other PRRs on cancer risk have also been reported.

Our study of the genetic variances in LBP rs2232596 and CD14 rs4914 provided strong evidence of interactions between LPS-signaling-related genes and the risk of CRC, indicating that the genetic modulation of LPS-induced inflammation may contribute to CRC development and progression. TAMs with defective LPS responsiveness are common components of the micro-environment of different cancers. In addition, the current study and several previous studies revealed that functional polymorphisms in LPS-signaling-related genes are associated with various cancer risks. More studies are needed to shed light on the underlying genetic mechanisms.

Tobacco and alcohol exposure have been identified as high-risk factors for CRC. However, our data failed to show any significant associations of tobacco and/or alcohol exposure with CRC susceptibility. We found that smokers and drinkers carrying LBP rs2232596 polymorphisms had a higher risk of CRC. But only drinkers carrying CD14 rs4914 polymorphism showed modest risk of CRC. One possible explanation is that different mechanisms regulate tobacco-gene and alcohol-gene interactions. This study lacked detailed information on the smoking and drinking status of the subjects. Further stratification analysis is needed to evaluate the risk of lifestyle factors.

What mediates the observed association between gene polymorphisms and CRC susceptibility still remains unknown. It would be interesting to compare the serum levels of LBP and CD14 from different genotypes to examine the relationship between gene polymorphisms and their expression levels.

In conclusion, the functional G alleles in both LBP rs2232596 and CD14 rs4914 SNPs showed significant associations with a high CRC risk. Further studies are needed to elucidate the effects of these genotypes on gene transcription, expression and functions in CRC and other types of malignancies.

**COMMENTS**

**Background**

Colorectal carcinoma (CRC) is a leading cause of cancer death in China and throughout the world. Chronic inflammation is considered to be important in the carcinogenesis of CRC. In this study, the authors examined the association between the gene polymorphisms of several lipopolysaccharide (LPS)-signaling factors and the risk of CRC to better elucidate the mechanism of inflammation in tumorigenesis.

**Research frontiers**

LPS-induced signaling is an important innate immune response that involves many different molecules, such as lipopolysaccharide binding protein (LBP), cluster of differentiation 14 (CD14), and toll-like receptor 4 (TLR-4). Recently, it has become a hot area to employ polymorphism analysis to identify genetic mutations in the immune system that are significantly correlated with tumor development.

**Innovations and breakthroughs**

To date, there has been no study on the polymorphisms of LPS-signaling-related genes and CRC susceptibility in the Chinese Han population. In this study, the authors directly addressed this issue and performed genetic analysis to screen for polymorphisms that are associated with increased CRC risk. The authors also explored the gene-environment interactions by studying the effects of smoking or drinking exposure on CRC susceptibility.
Applications

By demonstrating the association of LBP rs2232596 and CD14 rs4914 polymorphisms with increased CRC risk, the authors identified two important biomarkers for predicting CRC and further improved the understanding of the inflammation-related mechanisms in CRC development.

Terminology

Single-nucleotide polymorphism (SNP): a DNA sequence variation occurring when a single nucleotide in the genome differs between members of the same biological species or paired chromosomes in an individual. SNP analysis can shed light on how genetic variations affect disease development in humans.

Peer review

This is an interesting well-conducted and well-written study.

REFERENCES

1. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871-876
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
3. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671-674
4. Porta C, Larghi P, Rimoldi M, Trotaro MG, Allavena P, Mantovani A, Sica A. Cellular and molecular pathways linking inflammation and cancer. Immunology 2009; 214: 761-777
5. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217
6. Dougherty ST, Eaves CJ, McBride WH, Dougherty CJ. Molecular mechanisms regulating TNF-alpha production by tumor-associated macrophages. Cancer Lett 1997; 111: 27-37
7. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008; 267: 204-215
8. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009; 181: 1894-1900
9. Sica A, Schioppa T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-727
10. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi D, Doni A, Vincenzo B, Pasqualini F, Vago L, Bolzoni M, Mantovani A, Sica A. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006; 107: 2112-2122
11. Duff MD, Mestre J, Maddal S, Yan ZP, Stapleton P, Daly JM. Analysis of gene expression in the tumor-associated macrophage. J Surg Res 2007; 142: 119-128
12. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66: 1-9
13. Heumann D, Roger T. Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 2002; 323: 59-72
14. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002; 23: 301-304
15. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GL. Assessment of the toll-like receptor 4 (Asp299Gly, Thr399Ile and interleukin-8-251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer 2007; 7: 70
16. Xu H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and Interleukin-1RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1694-1617
17. Nogueira de Souza NC, Brenna SM, Campos F, Syrjanen Kj, Baracat EC, Silva ID. Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 2006; 16: 1278-1282
18. McCarron SL, Edwards S, Evans PR, Gibb S, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-3372
19. Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, Ko W, Lee G. The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytofgenet 2009; 190: 88-92
20. Shih CM, Lee YL, Chiou HL, Chen W, Chang GC, Chou MC, Lin LY. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2006; 52: 15-20
21. National Center for Biotechnology Information, dbSNP database. Available from: http://www.ncbi.nlm.nih.gov/projects/SNP
22. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-151
23. Agnese DM, Calvano JE, Hahn SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SF. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186: 1522-1525
24. Vollmer T, Klessiek K, Dreier J. Lipopolysaccharide-binding protein (LBP) gene polymorphisms: rapid genotyping by real-time PCR and association with infective endocarditis. Clin Biochem 2009; 42: 1413-1419
25. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003; 124: 1103-1115
26. Olivieri F, Antonicelli R, Cardelli M, Marchegiani F, Cavallone L, Mocchegiani E, Franceschi C. Genetic polymorphisms of inflammatory cytokines and myocardial infarction in the elderly. Mech Ageing Dev 2006; 127: 552-559
27. Guo Q, Zhu J, Xia B. Polymorphism of CD14 gene but not the mutation of TLR4 gene is associated with colorectal cancer in Chinese patients. J Gastroenterol Hepatol 2006; 21: 92-97
28. Zhao D, Sun T, Zhang X, Guo Y, Yu D, Yang M, Tan W, Wang G, Lin D. Role of CD14 promoter polymorphisms in Helicobacter pylori infection–related gastric carcinoma. Clin Cancer Res 2007; 13: 2362-2368
29. Mason TE, Ricks-Santi L, Chen W, Apprey V, Joykutty J, Aghanotu C, Kittles R, Bonney G, Dunston GM. Association of CD14 variant with prostate cancer in African American men. Prostate 2010; 70: 262-269
30. Fukata M, Abreu MT. Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol 2009; 9: 680-687
31. Kutikhin AG. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol 2011; 72: 193-206
32. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 725-731
33. Thyesgen LC, Wu K, Grenbaek M, Fuchs CS, Willett WC. Giovannucci E. Alcohol intake and colorectal cancer: a comparison of approaches for including repeated measured data on alcohol consumption. Epidemiology 2008; 19: 258-264

S- Editor Tian L E- Editor Ma WH